{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:06:19Z","timestamp":1762113979020,"version":"build-2065373602"},"reference-count":15,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p><jats:bold>Background\/Objective:<\/jats:bold> Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have a high morbidity of anosmia, yet there are few noninvasive biomarkers to measure treatment response. Nitric oxide (NO) is found in the paranasal sinuses at 100 times higher levels than\n in the lungs and is vital for antimicrobial and\/or mucociliary activities and vasodilatory properties. Dupilumab has been shown to improve anosmia in 2 weeks as measured by the University of Pennsylvania Smell Identification Test (UPSIT), 22-item Sinonasal Outcome Test (SNOT-22), and Loss\n of Smell (LoS) scoring. We examined the use of NO in various collection methods to monitor anosmia improvement with dupilumab treatment.  <jats:bold>Methods:<\/jats:bold> Adults with CRSwNP confirmed by computer tomography or endoscopy consented to receive dupilumab 300 mg every two weeks for 16\n weeks. Subjects with polyposis despite treatment with steroids and\/or a history of sinus surgery were recruited. Measurements of sinus NO (sNO) from the nostril while humming, nasal NO (nNO) while breath-holding, and fractional exhaled nitric oxide (FeNO) while exhaling were collected at baseline\n and at 1, 2, 4, 8, 12, 16 weeks. Olfactory impairment was measured by using the UPSIT, SNOT-22, and LoS scoring at every visit.  <jats:bold>Results:<\/jats:bold> Sixteen adults, with a mean (range) age of 43 years (25\u201053 years) were predominantly women (12\/16). Baseline mean (range) sNO\n values of 434 ppb (203\u2010665 ppb) significantly increased at 2 weeks to a mean (range) of 1150 ppb (684\u20101616 ppb) (p &lt; 0.05). Significant improvements in the UPSIT, SNOT-22, and LoS scores were found at 2 weeks; a weak correlation of the sNO level with the UPSIT and SNOT-22\n scores was noted. No significant changes in the FeNO or nNO values were found. Significant improvement was found specifically with anosmia by the end of 2 weeks.  <jats:bold>Conclusion:<\/jats:bold> Our small pilot study revealed increased sNO levels in the sinuses as early as 2 weeks after the\n initial dupilumab administration. Thus, in patients with CRSwNP without asthma, the sNO value has the potential to be used as a noninvasive, objective biomarker for early treatment improvement in anosmia.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250004","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T04:31:02Z","timestamp":1740630662000},"page":"105-108","source":"Crossref","is-referenced-by-count":2,"title":["Early clinical improvement of anosmia and sinus nitric oxide in chronic rhinosinusitis with nasal polyps subjects treated with dupilumab"],"prefix":"10.2500","volume":"46","author":[{"given":"Miguel J.","family":"Lanz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia P.","family":"Eisenlohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianet Herrera","family":"Cepeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1744666X.2018.1512407","article-title":"Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps","volume":"14","author":"Heffler","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nm0495-370","article-title":"High nitric oxide production in human paranasal sinuses","volume":"1","author":"Lundberg","year":"1995","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1183\/09031936.03.00017903","article-title":"Assessment of nasal and sinus nitric oxide using single-breath humming exhalations","volume":"22","author":"Maniscalco","year":"2003","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jcm9010200","article-title":"Nasal nitric oxide in chronic rhinosinusitis with or without nasal polyps: a systematic review with meta-analysis","volume":"9","author":"Ambrosino","year":"2020","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.3390\/ijms25084460","article-title":"Olfactory loss in rhinosinusitis: mechanisms of loss and recovery","volume":"25","author":"Dekeyser","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","article-title":"Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","article-title":"Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis","volume":"44","author":"Peters","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1081-1206(10)60310-9","article-title":"Nasal nitric oxide concentration in suspected chronic rhinosinusitis","volume":"101","author":"Bommarito","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/alr.23073","article-title":"Chronic interleukin-13 expression in mouse olfactory mucosa results in regional aneuronal epithelium","volume":"13","author":"Saraswathula","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2022.12.826","article-title":"IL-13-associated epithelial remodelling correlates with clinical severity in nasal polyposis","volume":"151","author":"Kotas","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/1744666X.2023.2235891","article-title":"Olfactory dysfunction in chronic rhinosinusitis: insights into the underlying mechanisms and treatments","volume":"19","author":"Song","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.18176\/jiaci.0851","article-title":"Very rapid improvement in extended nitric oxide parameters is associated with clinical and functional improvement in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab","volume":"33","author":"Paoletti","year":"2023","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000002\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:35:23Z","timestamp":1741149323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["1088-5412(20250301)46:2L.105;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250004","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}